TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis.
Brief Summary: Study will assess the safety and effectiveness of 12 week treatment with the study medication, Bronchitol, in subjects with bronchiectasis (a lung disease where patients have trapped, and often infected, thick, sticky mucus). Past studies have shown Bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology (making it less thick and sticky), thereby enhancing the shift of stagnant mucus from the lungs. On completion of the double blind phase, subjects will have the opportunity to participate in a 52 week open label phase.


Options:
A: Arm Label: Azithromycin treatment 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin treatment 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo 2
B: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis.
Brief Summary: Study will assess the safety and effectiveness of 12 week treatment with the study medication, Bronchitol, in subjects with bronchiectasis (a lung disease where patients have trapped, and often infected, thick, sticky mucus). Past studies have shown Bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology (making it less thick and sticky), thereby enhancing the shift of stagnant mucus from the lungs. On completion of the double blind phase, subjects will have the opportunity to participate in a 52 week open label phase.


Options:
A: Arm Label: HFCWO Arm; Type: EXPERIMENTAL; Interventions: Device: Airway clearance Device | Arm Label: CPT Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Airway clearance Device; Assigned to Arm(s): HFCWO Arm
B: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy
C: Arm Label: HFCWC with higher pressure/variable frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Arm Label: HFCWC with lower pressure/mid-frequency settings; Type: ACTIVE_COMPARATOR; Interventions: Device: HFCWC with higher pressure/variable-frequency settings, Device: HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with higher pressure/variable-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings | Intervention Type: DEVICE; Name: HFCWC with lower pressure/mid-frequency settings; Assigned to Arm(s): HFCWC with higher pressure/variable frequency settings, HFCWC with lower pressure/mid-frequency settings
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multicenter, Randomised, Parallel, Placebo-Controlled, Double-Blind Study to Investigate the Safety and Efficacy of Treatment With Bronchitol (Dry Powder Mannitol) in the Symptomatic Treatment of Bronchiectasis.
Brief Summary: Study will assess the safety and effectiveness of 12 week treatment with the study medication, Bronchitol, in subjects with bronchiectasis (a lung disease where patients have trapped, and often infected, thick, sticky mucus). Past studies have shown Bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology (making it less thick and sticky), thereby enhancing the shift of stagnant mucus from the lungs. On completion of the double blind phase, subjects will have the opportunity to participate in a 52 week open label phase.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline 6% - | Intervention Type: DRUG; Name: Hypertonic saline 6% -; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: OTHER; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protective Mechanisms of Aldosterone Antagonists and Their Effects on Cardiovascular Damage in Chronic Renal Failure: Clinical and Experimental Studies
Brief Summary: The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.


Options:
A: Intervention Type: DRUG; Name: Spironolactone (drug); Assigned to Arm(s): N/A
B: Arm Label: Eplerenone; Type: EXPERIMENTAL; Interventions: Drug: eplerenone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eplerenone; Assigned to Arm(s): Eplerenone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Spirnolactone; Type: EXPERIMENTAL; Interventions: Drug: spironolactone | Intervention Type: DRUG; Name: spironolactone; Assigned to Arm(s): Spirnolactone
D: Arm Label: Eplerenone group; Type: EXPERIMENTAL; Interventions: Drug: Eplerenone | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): Eplerenone group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Brief Summary: The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.


Options:
A: Arm Label: Desvenlafaxine Succinate Sustained-Release; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Intervention Type: DRUG; Name: DVS SR; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release
B: Intervention Type: DRUG; Name: DVS-SR 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: DVS-SR 100 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder
Brief Summary: The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.


Options:
A: Arm Label: Placebo + ADT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brexpiprazole + ADT; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Arm Label: Seroquel XR + ADT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Seroquel XR | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole + ADT | Intervention Type: DRUG; Name: Seroquel XR; Assigned to Arm(s): Seroquel XR + ADT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + ADT
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IBBIS MHC; Type: EXPERIMENTAL; Interventions: Behavioral: IBBIS mental health care and standard vocational rehabilitation | Arm Label: IBBIS integrated MCH and VR; Type: EXPERIMENTAL; Interventions: Other: Integrated mental health care and vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: IBBIS mental health care and standard vocational rehabilitation; Assigned to Arm(s): IBBIS MHC | Intervention Type: OTHER; Name: Integrated mental health care and vocational rehabilitation; Assigned to Arm(s): IBBIS integrated MCH and VR
C: Intervention Type: DRUG; Name: DVS-SR 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: DVS-SR 100 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2 Brief Supportive Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: BEHAVIORAL; Name: Brief Supportive Therapy; Assigned to Arm(s): 2 Brief Supportive Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Complications of Jugular and Femoral Venous Catheterization in Critically Ill Patients Requiring Hemodialysis: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether a jugular route leads to a lower rate of complications as compared with a femoral route for catheterization in patients admitted in several intensive care units in France who develop acute renal failure requiring hemodiafiltration or hemodialysis.


Options:
A: Arm Label: Femoral route; Type: EXPERIMENTAL; Interventions: Procedure: Femoral route for hemodialysis | Arm Label: Jugular route; Type: EXPERIMENTAL; Interventions: Procedure: Jugular route for hemodialysis | Intervention Type: PROCEDURE; Name: Femoral route for hemodialysis; Assigned to Arm(s): Femoral route | Intervention Type: PROCEDURE; Name: Jugular route for hemodialysis; Assigned to Arm(s): Jugular route
B: Arm Label: High dose CRRT; Type: EXPERIMENTAL; Interventions: Drug: high dose CRRT | Arm Label: Conventional dose CRRT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional dose CRRT | Intervention Type: DRUG; Name: high dose CRRT; Assigned to Arm(s): High dose CRRT | Intervention Type: DRUG; Name: Conventional dose CRRT; Assigned to Arm(s): Conventional dose CRRT
C: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2
D: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Linkage of Alcohol Abusers to Primary Care
Brief Summary: The objective of this study is to test whether a chronic disease management (CDM) program for substance abusers in primary care leads to improved alcohol and drug-related outcomes (such as reduced consumption and health problems) and health care utilization patterns.


Options:
A: Arm Label: 1) CDM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Chronic Disease Management for substance abuse | Arm Label: 2) Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Chronic Disease Management for substance abuse; Assigned to Arm(s): 1) CDM | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): 2) Standard care
B: Arm Label: Naltrexone alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Naltrexone | Arm Label: Naltrexone with CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-Behavioral Therapy, Drug: Naltrexone | Arm Label: Placebo with CBT for PTSD; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive-Behavioral Therapy | Arm Label: Placebo alone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavioral Therapy; Assigned to Arm(s): Naltrexone with CBT for PTSD, Placebo with CBT for PTSD | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Naltrexone alone, Naltrexone with CBT for PTSD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo alone
C: Arm Label: Seeking Safety; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Modified Seeking Safety integrated into std outpatient SUD care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard outpatient SUD care | Intervention Type: BEHAVIORAL; Name: Modified Seeking Safety integrated into std outpatient SUD care; Assigned to Arm(s): Seeking Safety | Intervention Type: BEHAVIORAL; Name: Standard outpatient SUD care; Assigned to Arm(s): Usual Care
D: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial
Brief Summary: Scleroderma is a systemic disorder categorized as an immunologically mediated disease that causes collagen deposition of skin and visceral organs. The molecular pathogenesis of scleroderma has been elusive, although vasculopathy and immune mediated mechanisms are thought to be important. Once extensive cutaneous or visceral disease occurs, prognosis is significantly shorter than the general population. Although various treatments have been tried, none of them seems to have changed the natural history of scleroderma. Standard dose immunosuppressive treatment has been disappointing. Recently, cyclophosphamide at 1-2 mg/kg/day orally or 800-1400 mg intravenous (IV) monthly for 6-9 months has proven effective in treatment of scleroderma alveolitis (1). Recent phase I studies of immunoablation with autologous peripheral blood stem cell transplantation (PBSCT) showed some promising data, but the exact efficacy is undetermined (2,3). We now propose, as a phase II randomized study, autologous unmanipulated PBSCT versus pulse cyclophosphamide in patients with systemic scleroderma.


Options:
A: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
B: Arm Label: Cylophosphamide; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cylophosphamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: mHSCT; Type: EXPERIMENTAL; Interventions: Biological: mHSCT | Arm Label: cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide | Intervention Type: BIOLOGICAL; Name: mHSCT; Assigned to Arm(s): mHSCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): cyclophosphamide
D: Arm Label: stem cell trasplantation; Type: EXPERIMENTAL; Interventions: Procedure: stem cell transplantation | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care | Intervention Type: PROCEDURE; Name: stem cell transplantation; Assigned to Arm(s): stem cell trasplantation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus: Phase II Trial
Brief Summary: This study is designed to examine whether treating patients with lupus with high dose cyclophosphamide together with rATG/rituximab (drugs which reduce the function of the immune system), followed by return of their previously collected stem cells will result in improvement in the disease. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the intense chemotherapy is to destroy the cells in the immune system which may be causing this disease. The purpose of the stem cell infusion is to produce a normal immune system that will no longer attack body. The study purpose is to examine whether this treatment will result in improvement in the lupus disease.


Options:
A: Arm Label: ASCs; Type: EXPERIMENTAL; Interventions: Drug: ASCs (Cx401, company code) | Arm Label: ASCs+fibrin glue; Type: EXPERIMENTAL; Interventions: Drug: ASCs (Cx401, company code), Drug: Fibrin adhesive | Arm Label: Fibrin glue; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrin adhesive | Intervention Type: DRUG; Name: ASCs (Cx401, company code); Assigned to Arm(s): ASCs, ASCs+fibrin glue | Intervention Type: DRUG; Name: Fibrin adhesive; Assigned to Arm(s): ASCs+fibrin glue, Fibrin glue
B: Arm Label: Hematopoietic Stem Cell Transplant Regimen 2; Type: EXPERIMENTAL; Interventions: Biological: Hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: Hematopoietic stem cell transplantation; Assigned to Arm(s): Hematopoietic Stem Cell Transplant Regimen 2
C: Arm Label: Transplant Arm; Type: EXPERIMENTAL; Interventions: Procedure: Autologous haematopoietic stem cell transplant | Arm Label: Delayed Transplant; Type: EXPERIMENTAL; Interventions: Procedure: Autologous haematopoietic stem cell transplant | Intervention Type: PROCEDURE; Name: Autologous haematopoietic stem cell transplant; Assigned to Arm(s): Delayed Transplant, Transplant Arm
D: Arm Label: Mesenchymal stromal cells; Type: EXPERIMENTAL; Interventions: Drug: Mesenchymal stromal cells (MSC) for infusion | Intervention Type: DRUG; Name: Mesenchymal stromal cells (MSC) for infusion; Assigned to Arm(s): Mesenchymal stromal cells

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Effectiveness Trial Examining the Addition of Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting.
Brief Summary: Several studies have shown the beneficial effect of zinc treatment in acute diarrhea. There was a significant reduction in duration of the treated episodes and in their severity as measured by diarrheal stool output or frequency. Zinc is a potentially important immunomodulator or nutraceutical which may have great impact as therapeutic agent in conditions like diarrhea and pneumonia. The issue is whether and how zinc should be introduced in primary health care programs for treatment of acute diarrhea. A practical, sustainable intervention for introduction of zinc as treatment of acute diarrhoea in national programs is therefore required. This study aimed to address this issue.


Options:
A: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Solar Water Disinfection (SODIS) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Solar Water Disinfection (SODIS); Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and ORS | Arm Label: 2; Type: OTHER; Interventions: Drug: ORS only | Intervention Type: DRUG; Name: Zinc and ORS; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ORS only; Assigned to Arm(s): 2

Answer: D